Fluvoxamine COVID-19 Treatment: Positive Impact on Patient Survival
pubmed.ncbi.nlm.nih.gov
Fluvoxamine treatment in addition to the standard therapy in hospitalised ICU COVID-19 patients could have a positive impact on patient survival. Further studies on the effects of fluvoxamine in COVID-19 patients are urgently required.
No statistically significant differences between groups were observed regarding the number of days on ventilator support, duration of ICU or total hospital stay. However, overall mortality was lower in the fluvoxamine group, 58.8% (n=30/51), than in the control group, 76.5% (n=39/51), HR 0.58, 95%CI (0.36 – 0.94, p = 0.027).
The study was designed as an open label, prospective cohort trial with matched controls.
Related Stories
Related Books
